Device Trial Radar · NCT06018194
ELUCIDATE FFRct Study
Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
439
Actual
Start
Sep 1, 2023
Primary completion
Jul 28, 2025
Study completion Jul 28, 2025
Sponsor
- Lead sponsor
- Elucid Bioimaging Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 30, 2023
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to evaluate the diagnostic accuracy of a novel plaque-based coronary CT angiography (CCTA) fractional flow reserve (FFRct) software device for the estimation of invasive fractional flow reserve (FFR). Researchers will compare the Elucid plaque-based FFRct analysis to invasively measured FFR in patients who have previously undergone CCTA and invasively assessed FFR.
Conditions
- Coronary Artery Disease
Interventions
ElucidVivoDevice
Plaque morphology characterization on coronary CTA for predicting fractional flow reserve (FFRct)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sensitivity of FFRct versus invasive FFR for detecting invasive FFR ≤ 0.80Time frame: 1 day
1 more outcomes with a free account
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Cardiovascular Medical Group of Southern California
Beverly Hills, California
7 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.